Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Titel:
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Auteur:
Bührer, Emanuel Kicinski, Michal Mandala, Mario Pe, Madeline Long, Georgina V Atkinson, Victoria Blank, Christian U Haydon, Andrew Dalle, Stéphane Khattak, Adnan Carlino, Matteo S Meshcheryakov, Andrey Sandhu, Shahneen Puig, Susana Schadendorf, Dirk Jamal, Rahima Rutkowski, Piotr van den Eertwegh, Alfonsus J M Coens, Corneel Grebennik, Dmitri Krepler, Clemens Robert, Caroline Eggermont, Alexander M M